[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"perinatal-and-neonatal-outcomes-in-pregnancies-with-type-2-diabetes-mellitus-t2dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:perinatal-and-neonatal-outcomes-in-pregnancies-with-type-2-diabetes-mellitus-t2dm":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":5},"100611487","antenatal-myo-inositol-supplementation-in-pre-existing-diabetes-100611487",false,"NCT07241221","Antenatal Myo-inositol Supplementation in Pre-existing Diabetes","Antenatal Myo-inositol Supplementation in Pre-existing Diabetes to Promote Normal Neonatal Outcomes","AMulet","Inclusion Criteria\n\n* Pregnant women aged 21 years to 45 years old at the time of recruitment\n* Ongoing, viable, singleton intrauterine pregnancy\n* Between 12+0 days-16+6 days weeks' gestation at recruitment\n* T2DM diagnosed by a documented 75g Oral Glucose Tolerance Test (OGTT) showing a fasting glucose of \\>7 mmol\u002FL or 2h glucose \\>11.1 mmol\u002FL, or an HbA1C \\>6.5%, either prior to pregnancy or during the first 16 weeks of the index pregnancy\n* Intend to receive antenatal care and give birth at NUH\n* Willing to provide written, informed consent\n* Able to swallow capsules and comply with trial procedures\n\nExclusion Criteria\n\n* Known or suspected fetal aneuploidy or genetic\u002Fstructural anomaly\n* Severe allergy to food items requiring carriage of an Epipen at all times","FEMALE","21 Years","45 Years",{"count":21,"type":22},182,"ESTIMATED","INTERVENTIONAL",[25],"NA","This feasibility pilot study aims to gather data that can guide the design of a larger, more comprehensive trial to establish the effects of myo-inositol supplementation on supporting healthy outcomes in pregnancies complicated by Type 2 Diabetes Mellitus (T2DM). It seeks to assess myo-inositol's potential to support fetal and neonatal health, and optimise maternity outcomes as a complementary approach and adjuvant to existing diabetes mellitus therapies, as well as investigate the underlying biological mechanisms.",[28],"Perinatal and Neonatal Outcomes in Pregnancies With Type 2 Diabetes Mellitus (T2DM)",[30,31,32,33,34,35,36,37,38,39,40,41],"Diabetes","Pregnancy","Myo-inositol","Folic acid","Dietary Supplement","Birthweight","Prematurity","Neonatal Intensive Care Unit Admission","Stillbirth","Neonatal Death","Neonatal Complications","Maternity Complications","RECRUITING","2025-12-02",{"date":45,"type":46},"2025-12-09","ACTUAL",{"date":48,"type":22},"2025-12",{"date":50,"type":22},"2029-08-31",{"name":52,"class":53},"National University Hospital, Singapore","OTHER"]